Aditxt, Inc. Amortization of Debt Issuance Costs
Aditxt, Inc. (ADTX) reported Amortization of Debt Issuance Costs of $1.53 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2023-04-17
- Aditxt, Inc. amortization of debt issuance costs for fiscal 2022 was $1.53M, a 16.92% decline from fiscal 2021.
- Aditxt, Inc. amortization of debt issuance costs for fiscal 2021 was $1.85M.
| Period end | Amortization of Debt Issuance Costs 12 month |
|---|---|
| 2022-12-31 | $1.53M 10-K · filed 2023-04-17 |
| 2021-12-31 | $1.85M 10-K · filed 2023-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |